Phase I Open-label, Parallel-group, Comparative Study to Evaluate the Effects of Renal or Hepatic Impairment on TAK-272 Pharmacokinetics With a Single Oral Administration of TAK-272 in Patients With Renal or Hepatic Impairment

Trial Profile

Phase I Open-label, Parallel-group, Comparative Study to Evaluate the Effects of Renal or Hepatic Impairment on TAK-272 Pharmacokinetics With a Single Oral Administration of TAK-272 in Patients With Renal or Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs TAK 272 (Primary)
  • Indications Diabetic nephropathies; Hypertension
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 05 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 29 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 22 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top